Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hybrisan Ltd. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action represents the company's active engagement with the patent office, reflecting a targeted approach to its intellectual property in the biotech sector. The matter is under the review of 1 distinct examiner, which means the company's current prosecution success is tied to a single individual's assessment.
The activity is localized in 1 distinct art unit, indicating a specific technical focus within the broader pharmaceutical field. RODRIGUEZ-GARCIA, VALERIE is the busiest examiner for the portfolio, handling 1 pending office action. Since this 1 action is the only one pending for the company, the examiner's specific interpretations of prior art and patentability will be the deciding factor for the portfolio's immediate progress. This concentration allows for a focused legal strategy but lacks the diversification of larger portfolios.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18700691 | COMPOSITION | RODRIGUEZ-GARCIA, VALERIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18700691 | COMPOSITION | RODRIGUEZ-GARCIA, VALERIE | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18700691 | COMPOSITION | RODRIGUEZ-GARCIA, VALERIE | 1621 | §102§103§112 | Non-Final OA | — | Pending | Apr 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHybrisan Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Valerie Rodriguez-Garcia has the most, with 1 of Hybrisan Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
